论文部分内容阅读
虽然阿司匹林与氯吡格雷双联抗血小板治疗后可降低经皮冠脉介入治疗(percutaneous coronary intervention,PCI)术后心血管事件的风险,但后续临床事件时有发生,氯吡格雷抵抗与PCI术后血栓事件存在直接关联。血管舒张剂刺激磷蛋白(vasodilator-stimulated phosphoprotein,VASP)磷酸化检测法是一种新型的用来确定ADP P2Y12受体阻断剂抑制血小板功能状态的新型检测方法,目前主要用于分析氯吡格雷抗血小板作用,同时可以预测PCI术后的主要不良心血管事件。
Although dual antiplatelet therapy with aspirin and clopidogrel may reduce the risk of cardiovascular events after percutaneous coronary intervention (PCI), subsequent clinical events may occur with clopidogrel resistance and PCI Post thrombotic events are directly related. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay is a novel assay to determine the inhibitory effect of ADP P2Y12 receptor blocker on platelet function. Currently, it is mainly used for the analysis of clopidogrel Anti-platelet function, at the same time can predict the main adverse cardiovascular events after PCI.